Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3965-3971

  Leyland Jones, Brian ^a   Gelmon, Karen ^a   Ayoub, Jean Pierre ^a   Arnold, Andrew ^a   Verma, Shail ^a   Dias, Reg ^a   Ghahramani, Parviz ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INJECTION SITE REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT RESPONSE; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; BREAST TUMOR; CANADA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CANADA; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENES, ERBB-2; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0346017700     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.109     Document Type: Article

References (27)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Chazin VR, Kaleko M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene 7:1859-1866, 1992
4. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
5. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
6. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
7. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
10. Leyland-Jones B: Dose scheduling: Herceptin. Oncology 61:31-36, 2001 (suppl 2)
11. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1995
12. Harris K, Washington CB, Lu J-F, et al: A population pharmacokinetic (PK) model for Herceptin (H) and implications for clinical dosing. Proc Am Soc Clin Oncol 21:123a, 2002 (abstr 488)
13. Konecny G, Pegram MD, Beryt M, et al: Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 57:114, 1999 (abstr 467)
14. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
15. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
16. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
17. Cresteil T, Monserrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392, 1994
18. Gianni L, Albanell J, Eiermann W, et al: Feasibility, pharmacology, and antitumour activity of Herceptin (H) with doxorubicin and Taxol followed by weekly Taxol (AT & T) in women with HER2-positive advanced breast cancer (ABC). Proc Am Soc Clin Oncol 20:44a, 2001 (abstr 174)
19. Carbonell Castellon X, Castaneda-Soto NJ, Clemens M, et al: Efficacy and safety of 3-weekly Herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): Preliminary data from a phase II study. Proc Am Soc Clin Oncol 21:19a, 2002 (abstr 73)
20. Ghahramani P, Barton C, Leyland-Jones B. Pharmacokinctics of Herceptin administered three-weekly compared to weekly: A simulation based on data from the clinical studies. Breast 12:S40, 2003 (suppl 1, abstr P89)
21. Gianni L, Eiermann W, Albanell J, et al: Cardiac safety and antitumour activity of doxorubicin and Taxol followed by weekly Taxol (AT & T) when Herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer. Eur J Cancer 37:S191, 2001 (suppl 6, abstr 698)
22. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61:58-66, 2001 (suppl 2)
23. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
24. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
25. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
26. Jahanzeb M, Mortimer JE, Yunus F, et al: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 7:410-417, 2002
27. Sambrook RJ, Girling DJ: A national survey of the chemotherapy regimens used to treat small cell lung cancer in the United Kingdom. Br J Cancer 84:1447-1452, 2001